Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Clinical Trials

Clinical Trials at The Methodist Hospital Research Institute

Search results...



NEUROSTIMULATION
Study Status: Active/Enrolling
Investigator: Estep, Jerry
Study Coordinator: Karanja, Eunice
Phone: 713-441-3571
Summary:The purpose of this study is to study the use of neurostimulation in chronic advanced refractory heart failure. The study is determine if it is safe to use neurostimulation in patients with chronic a...(read more)

Blood and Lymph Conditions

Active and enrolling clinical trials for Blood and Lymph Conditions are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Embolism and Thrombosis

Ovation
Study Status: Active/Enrolling
Investigator: Lumsden, Alan
Study Coordinator: Elliott, Dawn
Phone: 713-441-6536
Summary:The primary objectives of this study are to determine whether the TriVascular AAA Stent Graft is a safe and effective method of treating abdominal aortic aneurysms (AAA's) in those patients considered...(read more)
Hematologic Cancers

ENDEAVOR Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:This Phase 3 study is a multicenter, open-label, randomized trial in patients with multiple myeloma whose disease has relapsed after at least 1 but not more than 3 prior therapeutic regimens. Patients...(read more)

GDC-0199 and Obinutuzumab in Chronic Lymphocytic Leukemia
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Dotting , Andrea
Phone: 713-441-8029
Summary:This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics of GDC-0199 (ABT-199) administered in combination with obinutuzumab to patients with relapsed/refractory...(read more)
Lymphoma

C14012: Alisertib or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexat...(read more)

GDC-0199 and Obinutuzumab in Chronic Lymphocytic Leukemia
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Dotting , Andrea
Phone: 713-441-8029
Summary:This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics of GDC-0199 (ABT-199) administered in combination with obinutuzumab to patients with relapsed/refractory...(read more)

MLN8237 in Relapsed or Refractory Aggressive B-Cell Lymphoma - C14011
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Woodard, Karen
Phone: 713-441-4332
Summary:This is a single-arm, open-label, multicenter, dose escalation, phase 1-2 study of alisertib (MLN8237) administered in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)/transf...(read more)

OMB113676 Head to Head Trial of Ofatumumab versus Rituximab
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:This is a multi-center, parallel, active comparator controlled, open-label, randomized (1:1) phase III study of single agent ofatumumab compared to single agent rituximab in subjects with rituximab-se...(read more)

Cancers and Other Neoplasms

Active and enrolling clinical trials for Cancers and Other Neoplasms are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Brain and Central Nervous System Cancers

NovoCure EF-14
Study Status: Active/Enrolling
Investigator: New, Pamela
Study Coordinator: Harris, Kimbra
Phone: 713-441-3834
Summary:The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care in the treatm...(read more)

RTOG 0929
Study Status: Active/Enrolling
Investigator: New, Pamela
Study Coordinator: Harris, Kimbra
Phone: 713-441-3834
Summary:RATIONALE: ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide. work in different ways to stop the growt...(read more)
Brain Cancers

NovoCure EF-14
Study Status: Active/Enrolling
Investigator: New, Pamela
Study Coordinator: Harris, Kimbra
Phone: 713-441-3834
Summary:The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care in the treatm...(read more)
Breast Cancers

CA216.001 BMS906024 in Subjects With Advanced or Metastatic Solid Tumor
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects with advanced or metastatic solid tumors who no longer respond to or have relapsed from standard therapies.(read more)

CAT Trial
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The major purpose of this research study is to better understand how therapy works on different patients. This study is being offered to patients with a diagnosis of advanced or metastatic breast canc...(read more)

Denosumab - Breast Cancer
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:Purpose: This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therap...(read more)

Ganetespib STA-9090 for Metastatic HER2 Positive or Triple Negative Breast Cancer
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The purpose of this study is to determine if ganetespib (STA-9090) is effective in the treatment of patients with HER2+ or triple negative breast cancer who have not received prior systemic treatment ...(read more)

ICE Trial
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:Ixabepilone and capecitabine combination has demonstrated to be an active regimen in patients with metastatic breast cancer (MBC) after failing an anthracycline and a taxane regimen. Cetuximab is acti...(read more)

Katherine, B50, for Treatment of Adjuvant HER2 Positive Breast Cancer
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have res...(read more)

M12-895 Abbott Phase II
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The Study Evaluating Efficacy And Tolerability of Veliparib in Combination with Temozolomide or Veliparib/Placebo in Combination with Carboplatin and Paclitaxel in Subjects with Breast Cancer Gene (BR...(read more)

NECTAR Everolimus plus Cisplatin in Triple (-) Breast Cancer
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:PURPOSE: The purpose of this study is to test how effective combing a Cisplatin chemotherapy with Everolimus is in treating subjects with residual triple negative breast cancer, who have already recei...(read more)

NSABP B43
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or...(read more)

NSABP B47
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination ch...(read more)

Olive Oil for Breast Cancer Prevention in Women at High Risk for Breast Cancer
Study Status: Active/Enrolling
Investigator: Patel, Tejal
Study Coordinator: Bass, Anastasia
Phone: 713-441-8389
Summary:This is a pilot study is evaluating the effect of hydroxytyrosol, a component of Olive oil, on mammographic density in women at high risk of breast through assessing whether mammographic density is re...(read more)

PREDATOR TRIAL
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:The purpose of this phase II study is to find out if the test, Mammostrat® can be used as a predictor or outcome tool to determine who will best benefit from chemotherapy prior to surgery. This can be...(read more)

PROMIS registry of mammaprint in breast cancer
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:This is a prospective registry study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.(read more)

REP0210: Reparixin in early breast cancer patients prior to surgery
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:This is a pilot "window of opportunity" clinical study in patients with operable breast cancer investigating use of reparixin as single agent in the time period between clinical diagnosis and surgery....(read more)

S0812 Vitamin D in High Risk Breast Cancer
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:RATIONALE: Cholecalciferol may prevent breast cancer in premenopausal women. PURPOSE: This randomized phase II trial is studying how well cholecalciferol works in preventing breast cancer in premenop...(read more)

SWOG 1007
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibit...(read more)

Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The purpose of this study is to compare active immunotherapy (OPT-822/OPT-821) with PBS in combination with low dose cyclophosphamide, in post-treated metastatic breast cancer subjects with stable dis...(read more)

Triple Negative RAD 001
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everol...(read more)
Colon and Colorectal Cancer

CA216.001 BMS906024 in Subjects With Advanced or Metastatic Solid Tumor
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects with advanced or metastatic solid tumors who no longer respond to or have relapsed from standard therapies.(read more)
Hematologic Cancers

ENDEAVOR Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:This Phase 3 study is a multicenter, open-label, randomized trial in patients with multiple myeloma whose disease has relapsed after at least 1 but not more than 3 prior therapeutic regimens. Patients...(read more)

GDC-0199 and Obinutuzumab in Chronic Lymphocytic Leukemia
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Dotting , Andrea
Phone: 713-441-8029
Summary:This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics of GDC-0199 (ABT-199) administered in combination with obinutuzumab to patients with relapsed/refractory...(read more)
Lung Cancers

CA216.001 BMS906024 in Subjects With Advanced or Metastatic Solid Tumor
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects with advanced or metastatic solid tumors who no longer respond to or have relapsed from standard therapies.(read more)

GALAXY 2 TRIAL Ganetespib w/Docetaxel vs Docetaxel alone in patients w/advanced NSCLC
Study Status: Active/Enrolling
Investigator: Bernicker, Eric
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced non-small cell lung c...(read more)

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
Study Status: Active/Enrolling
Investigator: Bernicker, Eric
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:The primary purpose of the study is to compare the antitumor activity of LDK378 vs. chemotherapy in patients previously treated with chemotherapy (platinum doublet) and crizotinib.(read more)

OAK TRIAL - MPDL3280A with Docetaxel in Patients with Non-Small Cell Lung Cancer After Failure with Platinum-Containing Chemotherapy
Study Status: Active/Enrolling
Investigator: Bernicker, Eric
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:This global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of MPDL3280A compared with docetaxel in patients with locally advanced or metastatic non-small ...(read more)

S0819 Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab w/ or w/out Cetuximab in Patients with NSCLC
Study Status: Active/Enrolling
Investigator: Bernicker, Eric
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Mono...(read more)
Lymphoma

C14012: Alisertib or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexat...(read more)

GDC-0199 and Obinutuzumab in Chronic Lymphocytic Leukemia
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Dotting , Andrea
Phone: 713-441-8029
Summary:This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics of GDC-0199 (ABT-199) administered in combination with obinutuzumab to patients with relapsed/refractory...(read more)

MLN8237 in Relapsed or Refractory Aggressive B-Cell Lymphoma - C14011
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Woodard, Karen
Phone: 713-441-4332
Summary:This is a single-arm, open-label, multicenter, dose escalation, phase 1-2 study of alisertib (MLN8237) administered in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)/transf...(read more)

OMB113676 Head to Head Trial of Ofatumumab versus Rituximab
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:This is a multi-center, parallel, active comparator controlled, open-label, randomized (1:1) phase III study of single agent ofatumumab compared to single agent rituximab in subjects with rituximab-se...(read more)
Ovarian & Fallopian Tube Cancers

GOG-0225
Study Status: Active/Enrolling
Investigator: Kamat, Aparna
Study Coordinator: Kamath, Jaya
Phone: 713-441-6616
Summary:This randomized phase III trial is studying diet and physical activity changes to see how well they work compared with usual care in improving progression-free survival of patients with previously tre...(read more)
Prostate Cancers

LUTS Pilot - VESI-11E02
Study Status: Active/Enrolling
Investigator: Boone, Timothy
Study Coordinator: Whipple, Melissa
Phone: 713-441-3247
Summary:A single center, pilot trial with combination therapy of tamsulosin and solifenacin in 20 men with symptomatic lower urinary tract symptoms (LUTS). Subjects will be evaluated at baseline, 1, 2, and 3 ...(read more)

Digestive System Diseases

Active and enrolling clinical trials for Digestive System Diseases are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Cirrhosis

Salix: Rifaximin / Hepatic Encephalopathy study
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.(read more)

Salix: Rifaximin Soluble Solid Dispersion SSD Tablets for Decompensated Liver Cirrhosis
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:The primary objective of this study is to assess the efficacy of rifaximin SSD versus placebo in preventing complications of liver cirrhosis, such as all-cause mortality (death due to all causes) or h...(read more)
Colon and Colorectal Cancer

CA216.001 BMS906024 in Subjects With Advanced or Metastatic Solid Tumor
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects with advanced or metastatic solid tumors who no longer respond to or have relapsed from standard therapies.(read more)
Diabetes Mellitus

EXSCEL
Study Status: Active/Enrolling
Investigator: Davies, Mark
Study Coordinator: Elliott, Dawn
Phone: 713-441-6536
Summary:This study will compare the impact of including exenatide once weekly as part of usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary cardiovascular ...(read more)
Hepatitis Infections

Post-marketing registry of renal safety of HBV+ awaiting liver transplant
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:This registry will remain open for approximately 5 years. Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry. W...(read more)
Liver Diseases

Post-marketing registry of renal safety of HBV+ awaiting liver transplant
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:This registry will remain open for approximately 5 years. Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry. W...(read more)

Salix: Rifaximin / Hepatic Encephalopathy study
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.(read more)
Liver Transplant

Salix: Rifaximin / Hepatic Encephalopathy study
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.(read more)

Diseases and Abnormalities at or before Birth

Active and enrolling clinical trials for Diseases and Abnormalities at or before Birth are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Heart Defects

AC-058B201 Echocardiographic Ancillary Study
Study Status: Active/Enrolling
Investigator: Nagueh, Sherif
Study Coordinator: Frias, Maria
Phone: 713-441-2849
Summary:Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of ACT-128800, an Oral S1P1 Receptor ...(read more)

Corevalve Extreme Risks Patients
Study Status: Active/Enrolling
Investigator: Kleiman, Neal
Study Coordinator: Green, LaShawna
Phone: (713) 441-6548
Summary:The purpose of the study is to evaluate the safety and efficacy of the Medtronic CoreValve® System in the treatment of symptomatic severe aortic stenosis in subjects who have a predicted high risk for...(read more)

CoreValve High Risk Surgical Patients
Study Status: Active/Enrolling
Investigator: Reardon, Michael
Study Coordinator: Green, LaShawna
Phone: (713) 441-6548
Summary:The purpose of the study is to evaluate the safety and efficacy of the Medtronic CoreValve® System in the treatment of symptomatic severe aortic stenosis in subjects who have a predicted high risk for...(read more)

Gland and Hormone Related Diseases

Active and enrolling clinical trials for Gland and Hormone Related Diseases are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Breast Cancers

CA216.001 BMS906024 in Subjects With Advanced or Metastatic Solid Tumor
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects with advanced or metastatic solid tumors who no longer respond to or have relapsed from standard therapies.(read more)

CAT Trial
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The major purpose of this research study is to better understand how therapy works on different patients. This study is being offered to patients with a diagnosis of advanced or metastatic breast canc...(read more)

Denosumab - Breast Cancer
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:Purpose: This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therap...(read more)

Ganetespib STA-9090 for Metastatic HER2 Positive or Triple Negative Breast Cancer
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The purpose of this study is to determine if ganetespib (STA-9090) is effective in the treatment of patients with HER2+ or triple negative breast cancer who have not received prior systemic treatment ...(read more)

ICE Trial
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:Ixabepilone and capecitabine combination has demonstrated to be an active regimen in patients with metastatic breast cancer (MBC) after failing an anthracycline and a taxane regimen. Cetuximab is acti...(read more)

Katherine, B50, for Treatment of Adjuvant HER2 Positive Breast Cancer
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have res...(read more)

M12-895 Abbott Phase II
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The Study Evaluating Efficacy And Tolerability of Veliparib in Combination with Temozolomide or Veliparib/Placebo in Combination with Carboplatin and Paclitaxel in Subjects with Breast Cancer Gene (BR...(read more)

NECTAR Everolimus plus Cisplatin in Triple (-) Breast Cancer
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:PURPOSE: The purpose of this study is to test how effective combing a Cisplatin chemotherapy with Everolimus is in treating subjects with residual triple negative breast cancer, who have already recei...(read more)

NSABP B43
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or...(read more)

NSABP B47
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination ch...(read more)

Olive Oil for Breast Cancer Prevention in Women at High Risk for Breast Cancer
Study Status: Active/Enrolling
Investigator: Patel, Tejal
Study Coordinator: Bass, Anastasia
Phone: 713-441-8389
Summary:This is a pilot study is evaluating the effect of hydroxytyrosol, a component of Olive oil, on mammographic density in women at high risk of breast through assessing whether mammographic density is re...(read more)

PREDATOR TRIAL
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:The purpose of this phase II study is to find out if the test, Mammostrat® can be used as a predictor or outcome tool to determine who will best benefit from chemotherapy prior to surgery. This can be...(read more)

PROMIS registry of mammaprint in breast cancer
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:This is a prospective registry study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.(read more)

REP0210: Reparixin in early breast cancer patients prior to surgery
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:This is a pilot "window of opportunity" clinical study in patients with operable breast cancer investigating use of reparixin as single agent in the time period between clinical diagnosis and surgery....(read more)

S0812 Vitamin D in High Risk Breast Cancer
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:RATIONALE: Cholecalciferol may prevent breast cancer in premenopausal women. PURPOSE: This randomized phase II trial is studying how well cholecalciferol works in preventing breast cancer in premenop...(read more)

SWOG 1007
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibit...(read more)

Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The purpose of this study is to compare active immunotherapy (OPT-822/OPT-821) with PBS in combination with low dose cyclophosphamide, in post-treated metastatic breast cancer subjects with stable dis...(read more)

Triple Negative RAD 001
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everol...(read more)
Cirrhosis

Salix: Rifaximin / Hepatic Encephalopathy study
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.(read more)

Salix: Rifaximin Soluble Solid Dispersion SSD Tablets for Decompensated Liver Cirrhosis
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:The primary objective of this study is to assess the efficacy of rifaximin SSD versus placebo in preventing complications of liver cirrhosis, such as all-cause mortality (death due to all causes) or h...(read more)
Diabetes Mellitus

EXSCEL
Study Status: Active/Enrolling
Investigator: Davies, Mark
Study Coordinator: Elliott, Dawn
Phone: 713-441-6536
Summary:This study will compare the impact of including exenatide once weekly as part of usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary cardiovascular ...(read more)
Hepatitis Infections

Post-marketing registry of renal safety of HBV+ awaiting liver transplant
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:This registry will remain open for approximately 5 years. Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry. W...(read more)
Liver Diseases

Post-marketing registry of renal safety of HBV+ awaiting liver transplant
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:This registry will remain open for approximately 5 years. Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry. W...(read more)

Salix: Rifaximin / Hepatic Encephalopathy study
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.(read more)
Liver Transplant

Salix: Rifaximin / Hepatic Encephalopathy study
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.(read more)
Osteoporosis

P-15 Bone Putty in ACDF
Study Status: Active/Enrolling
Investigator: Baskin, David
Study Coordinator: Resendez, Darla
Phone: 713-441-3803
Summary:The aim of this trial is to evaluate if P-15 bone putty (investigational device) is not inferior in effectiveness and safety to local autologous bone (control device) when applied in instrumented ante...(read more)
Prostate Cancers

LUTS Pilot - VESI-11E02
Study Status: Active/Enrolling
Investigator: Boone, Timothy
Study Coordinator: Whipple, Melissa
Phone: 713-441-3247
Summary:A single center, pilot trial with combination therapy of tamsulosin and solifenacin in 20 men with symptomatic lower urinary tract symptoms (LUTS). Subjects will be evaluated at baseline, 1, 2, and 3 ...(read more)

Heart and Blood Diseases

Active and enrolling clinical trials for Heart and Blood Diseases are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Arrythmias

Hansen System with ThermoCool® for Patients with PAF
Study Status: Active/Enrolling
Investigator: Valderrabano, Miguel
Study Coordinator: Yrshus, Morgan
Phone: 713-441-3248
Summary:The purpose of this study is to assess the safety and performance of the Hansen Medical Sensei Robotic System and Artisan Catheter when used to robotically manipulate the Biosense ThermoCool ablation ...(read more)

IRASE AF
Study Status: Active/Enrolling
Investigator: Rami, Tapan
Study Coordinator: Tindel, Melinda
Phone: 713-441-3248
Summary:The purpose of this study is to test the safety and effectiveness of an Irrigated Ablation System for the treatment of symptomatic paroxysmal atrial fibrillation.(read more)
Atherosclerosis and Arteriosclerosis

Ovation
Study Status: Active/Enrolling
Investigator: Lumsden, Alan
Study Coordinator: Elliott, Dawn
Phone: 713-441-6536
Summary:The primary objectives of this study are to determine whether the TriVascular AAA Stent Graft is a safe and effective method of treating abdominal aortic aneurysms (AAA's) in those patients considered...(read more)
Cardiac Arrest

MIRACLE - EF
Study Status: Active/Enrolling
Investigator: Trachtenberg, Barry
Study Coordinator: Taylor, Emily
Phone: 713-441-3963
Summary:The MIRACLE EF study is a prospective, randomized, controlled, double-blinded, global multi-center, Cardiac Resynchronization Therapy (CRT) in Heart Failure (HF) clinical study. The study is expected...(read more)
Coronary Artery Disease

ABSORB RCT
Study Status: Active/Enrolling
Investigator: Shah, Alpesh
Study Coordinator: Garrett, Jennifer
Phone: 713-441-3959
Summary:A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions.(read more)

EXCEL
Study Status: Active/Enrolling
Investigator: Shah, Alpesh
Study Coordinator: Garrett, Jennifer
Phone: 713-441-3959
Summary:To establish the safety and efficacy of the XIENCE PRIME or XIENCE V Everolimus Eluting Coronary Stent System (EECSS) in subjects with unprotected left main coronary artery disease by comparing to cor...(read more)

EXPERT CTO
Study Status: Active/Enrolling
Investigator: Shah, Alpesh
Study Coordinator: Sosa, Lenis
Phone: 713-441-3245
Summary:A prospective, multi-center, single-arm study to establish the safety and effectiveness of the XIENCE V® Everolimus Eluting Coronary Stent, XIENCE nano™ Everolimus Eluting Coronary Stent, HT PROGRESS ...(read more)

IRASE AF
Study Status: Active/Enrolling
Investigator: Rami, Tapan
Study Coordinator: Tindel, Melinda
Phone: 713-441-3248
Summary:The purpose of this study is to test the safety and effectiveness of an Irrigated Ablation System for the treatment of symptomatic paroxysmal atrial fibrillation.(read more)
Embolism and Thrombosis

Ovation
Study Status: Active/Enrolling
Investigator: Lumsden, Alan
Study Coordinator: Elliott, Dawn
Phone: 713-441-6536
Summary:The primary objectives of this study are to determine whether the TriVascular AAA Stent Graft is a safe and effective method of treating abdominal aortic aneurysms (AAA's) in those patients considered...(read more)
Heart Attack (Myocardial Infarction)

AASTROM -55-1202-1
Study Status: Active/Enrolling
Investigator: Trachtenberg, Barry
Study Coordinator: Taylor, Emily
Phone: 713-441-3963
Summary:This is a phase 2b, Multicenter, Randomize, Double –blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of transendocardial injection of IXMYELOCEL-T in ...(read more)

MIRACLE - EF
Study Status: Active/Enrolling
Investigator: Trachtenberg, Barry
Study Coordinator: Taylor, Emily
Phone: 713-441-3963
Summary:The MIRACLE EF study is a prospective, randomized, controlled, double-blinded, global multi-center, Cardiac Resynchronization Therapy (CRT) in Heart Failure (HF) clinical study. The study is expected...(read more)
Heart Defects

AC-058B201 Echocardiographic Ancillary Study
Study Status: Active/Enrolling
Investigator: Nagueh, Sherif
Study Coordinator: Frias, Maria
Phone: 713-441-2849
Summary:Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of ACT-128800, an Oral S1P1 Receptor ...(read more)

Corevalve Extreme Risks Patients
Study Status: Active/Enrolling
Investigator: Kleiman, Neal
Study Coordinator: Green, LaShawna
Phone: (713) 441-6548
Summary:The purpose of the study is to evaluate the safety and efficacy of the Medtronic CoreValve® System in the treatment of symptomatic severe aortic stenosis in subjects who have a predicted high risk for...(read more)

CoreValve High Risk Surgical Patients
Study Status: Active/Enrolling
Investigator: Reardon, Michael
Study Coordinator: Green, LaShawna
Phone: (713) 441-6548
Summary:The purpose of the study is to evaluate the safety and efficacy of the Medtronic CoreValve® System in the treatment of symptomatic severe aortic stenosis in subjects who have a predicted high risk for...(read more)
Heart Failure

Freedom Driver
Study Status: Active/Enrolling
Investigator: Bruckner, Brian
Study Coordinator: Bunge, Raquel
Phone: 713-441-6509
Summary:The purposes of this study are to confirm that the Freedom Driver System is a suitable pneumatic driver for clinically stable TAH-t subjects, and that patients and lay caregivers can be trained to man...(read more)

SynCardia TAH-t PM Surveillance Study
Study Status: Active/Enrolling
Investigator: Bruckner, Brian
Study Coordinator: Bunge, Raquel
Phone: 713-441-6509
Summary:The purpose of this study is to demonstrate that the results achieved in the original pivotal clinical investigation of 81 subjects from five clinical sites are generalizable to new clinical sites tha...(read more)
Heart Transplant

CLINICAL TRIALS IN ORGAN TRANSPLANTATION CTOT-11
Study Status: Active/Enrolling
Investigator: Bhimaraj, Arvind
Study Coordinator: Karanja, Eunice
Phone: 713-441-3571
Summary:CTOT-11 STUDY Post heart transplant research study. The study will recruit 400 primary heart transplant recipients from the approximately 25 participating centers. Subjects will be screened, consented...(read more)

Freedom Driver
Study Status: Active/Enrolling
Investigator: Bruckner, Brian
Study Coordinator: Bunge, Raquel
Phone: 713-441-6509
Summary:The purposes of this study are to confirm that the Freedom Driver System is a suitable pneumatic driver for clinically stable TAH-t subjects, and that patients and lay caregivers can be trained to man...(read more)

SynCardia TAH-t PM Surveillance Study
Study Status: Active/Enrolling
Investigator: Bruckner, Brian
Study Coordinator: Bunge, Raquel
Phone: 713-441-6509
Summary:The purpose of this study is to demonstrate that the results achieved in the original pivotal clinical investigation of 81 subjects from five clinical sites are generalizable to new clinical sites tha...(read more)
Myocardial Ischemia

EXCEL
Study Status: Active/Enrolling
Investigator: Shah, Alpesh
Study Coordinator: Garrett, Jennifer
Phone: 713-441-3959
Summary:To establish the safety and efficacy of the XIENCE PRIME or XIENCE V Everolimus Eluting Coronary Stent System (EECSS) in subjects with unprotected left main coronary artery disease by comparing to cor...(read more)

EXPERT CTO
Study Status: Active/Enrolling
Investigator: Shah, Alpesh
Study Coordinator: Sosa, Lenis
Phone: 713-441-3245
Summary:A prospective, multi-center, single-arm study to establish the safety and effectiveness of the XIENCE V® Everolimus Eluting Coronary Stent, XIENCE nano™ Everolimus Eluting Coronary Stent, HT PROGRESS ...(read more)
Stroke

GTN
Study Status: Active/Enrolling
Investigator: Diaz, Orlando
Study Coordinator: Bautista, Marilyn
Phone: 713-441-3912
Summary:The current proposal describes a post-market, clinical registry of HydroSoft, aimed at gaining robust clinical data in a large set of patients to better define the advantages, and potentially, the dis...(read more)

Immune System Diseases

Active and enrolling clinical trials for Immune System Diseases are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Lymphoma

C14012: Alisertib or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexat...(read more)

GDC-0199 and Obinutuzumab in Chronic Lymphocytic Leukemia
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Dotting , Andrea
Phone: 713-441-8029
Summary:This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics of GDC-0199 (ABT-199) administered in combination with obinutuzumab to patients with relapsed/refractory...(read more)

MLN8237 in Relapsed or Refractory Aggressive B-Cell Lymphoma - C14011
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Woodard, Karen
Phone: 713-441-4332
Summary:This is a single-arm, open-label, multicenter, dose escalation, phase 1-2 study of alisertib (MLN8237) administered in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)/transf...(read more)

OMB113676 Head to Head Trial of Ofatumumab versus Rituximab
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:This is a multi-center, parallel, active comparator controlled, open-label, randomized (1:1) phase III study of single agent ofatumumab compared to single agent rituximab in subjects with rituximab-se...(read more)

Muscle, Bone, and Cartilage Diseases & Disorders

Active and enrolling clinical trials for Muscle, Bone, and Cartilage Diseases & Disorders are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Bone Diseases

P-15 Bone Putty in ACDF
Study Status: Active/Enrolling
Investigator: Baskin, David
Study Coordinator: Resendez, Darla
Phone: 713-441-3803
Summary:The aim of this trial is to evaluate if P-15 bone putty (investigational device) is not inferior in effectiveness and safety to local autologous bone (control device) when applied in instrumented ante...(read more)
Osteoporosis

P-15 Bone Putty in ACDF
Study Status: Active/Enrolling
Investigator: Baskin, David
Study Coordinator: Resendez, Darla
Phone: 713-441-3803
Summary:The aim of this trial is to evaluate if P-15 bone putty (investigational device) is not inferior in effectiveness and safety to local autologous bone (control device) when applied in instrumented ante...(read more)

Nervous System Diseases & Disorders

Active and enrolling clinical trials for Nervous System Diseases & Disorders are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Amyotrophic Lateral Sclerosis (ALS)

Pyrimethamine in FALS
Study Status: Active/Enrolling
Investigator: Appel, Stanley
Study Coordinator: Halton, Sharon
Phone: 713-441-3420
Summary:The objective of this study will be to evaluate the safety, tolerability and effect on SOD1 levels by pyrimethamine in patients with familial amyotrophic lateral sclerosis.(read more)
Brain and Central Nervous System Cancers

NovoCure EF-14
Study Status: Active/Enrolling
Investigator: New, Pamela
Study Coordinator: Harris, Kimbra
Phone: 713-441-3834
Summary:The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care in the treatm...(read more)

RTOG 0929
Study Status: Active/Enrolling
Investigator: New, Pamela
Study Coordinator: Harris, Kimbra
Phone: 713-441-3834
Summary:RATIONALE: ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide. work in different ways to stop the growt...(read more)
Brain Cancers

NovoCure EF-14
Study Status: Active/Enrolling
Investigator: New, Pamela
Study Coordinator: Harris, Kimbra
Phone: 713-441-3834
Summary:The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care in the treatm...(read more)
Neurodegenerative Diseases

AC-058B201 Echocardiographic Ancillary Study
Study Status: Active/Enrolling
Investigator: Nagueh, Sherif
Study Coordinator: Frias, Maria
Phone: 713-441-2849
Summary:Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of ACT-128800, an Oral S1P1 Receptor ...(read more)

Pyrimethamine in FALS
Study Status: Active/Enrolling
Investigator: Appel, Stanley
Study Coordinator: Halton, Sharon
Phone: 713-441-3420
Summary:The objective of this study will be to evaluate the safety, tolerability and effect on SOD1 levels by pyrimethamine in patients with familial amyotrophic lateral sclerosis.(read more)
Stroke

GTN
Study Status: Active/Enrolling
Investigator: Diaz, Orlando
Study Coordinator: Bautista, Marilyn
Phone: 713-441-3912
Summary:The current proposal describes a post-market, clinical registry of HydroSoft, aimed at gaining robust clinical data in a large set of patients to better define the advantages, and potentially, the dis...(read more)

Nutritional and Metabolic Conditions & Diseases

Active and enrolling clinical trials for Nutritional and Metabolic Conditions & Diseases are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Atherosclerosis and Arteriosclerosis

Ovation
Study Status: Active/Enrolling
Investigator: Lumsden, Alan
Study Coordinator: Elliott, Dawn
Phone: 713-441-6536
Summary:The primary objectives of this study are to determine whether the TriVascular AAA Stent Graft is a safe and effective method of treating abdominal aortic aneurysms (AAA's) in those patients considered...(read more)
Diabetes Mellitus

EXSCEL
Study Status: Active/Enrolling
Investigator: Davies, Mark
Study Coordinator: Elliott, Dawn
Phone: 713-441-6536
Summary:This study will compare the impact of including exenatide once weekly as part of usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary cardiovascular ...(read more)

Respiratory Tract (Lung and Bronchial) Diseases

Active and enrolling clinical trials for Respiratory Tract (Lung and Bronchial) Diseases are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Lung Cancers

CA216.001 BMS906024 in Subjects With Advanced or Metastatic Solid Tumor
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects with advanced or metastatic solid tumors who no longer respond to or have relapsed from standard therapies.(read more)

GALAXY 2 TRIAL Ganetespib w/Docetaxel vs Docetaxel alone in patients w/advanced NSCLC
Study Status: Active/Enrolling
Investigator: Bernicker, Eric
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced non-small cell lung c...(read more)

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
Study Status: Active/Enrolling
Investigator: Bernicker, Eric
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:The primary purpose of the study is to compare the antitumor activity of LDK378 vs. chemotherapy in patients previously treated with chemotherapy (platinum doublet) and crizotinib.(read more)

OAK TRIAL - MPDL3280A with Docetaxel in Patients with Non-Small Cell Lung Cancer After Failure with Platinum-Containing Chemotherapy
Study Status: Active/Enrolling
Investigator: Bernicker, Eric
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:This global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of MPDL3280A compared with docetaxel in patients with locally advanced or metastatic non-small ...(read more)

S0819 Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab w/ or w/out Cetuximab in Patients with NSCLC
Study Status: Active/Enrolling
Investigator: Bernicker, Eric
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Mono...(read more)

Symptoms and General Pathology

Active and enrolling clinical trials for Symptoms and General Pathology are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Cirrhosis

Salix: Rifaximin / Hepatic Encephalopathy study
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.(read more)

Salix: Rifaximin Soluble Solid Dispersion SSD Tablets for Decompensated Liver Cirrhosis
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:The primary objective of this study is to assess the efficacy of rifaximin SSD versus placebo in preventing complications of liver cirrhosis, such as all-cause mortality (death due to all causes) or h...(read more)
Headache

PREMIUM Trial
Study Status: Active/Enrolling
Investigator: Volpi, John
Study Coordinator: Wiese, Jonathan
Phone: 713-441-7161
Summary:The Purpose of this study is to evaluate the impact of percutaneous closure of a patent foramen ovale (a hole in the heart), using the AMPLATZER PFO Occluder, on the incidence of migraine headaches.(read more)

Transplant Trials

Active and enrolling clinical trials for Transplant Trials are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Graft Failure

LCP-Tacro 3002
Study Status: Active/Enrolling
Investigator: Knight, Richard
Study Coordinator: Brann, Sarah
Phone: 713-441-6394
Summary:This study will evaluate the efficacy and safety of LCP-Tacro (tacrolimus) Tablets administered once-a-day compared to Prograf (tacrolimus) Capsules twice-a-day as immunosuppression for the prevention...(read more)
Heart Transplant

CLINICAL TRIALS IN ORGAN TRANSPLANTATION CTOT-11
Study Status: Active/Enrolling
Investigator: Bhimaraj, Arvind
Study Coordinator: Karanja, Eunice
Phone: 713-441-3571
Summary:CTOT-11 STUDY Post heart transplant research study. The study will recruit 400 primary heart transplant recipients from the approximately 25 participating centers. Subjects will be screened, consented...(read more)

Freedom Driver
Study Status: Active/Enrolling
Investigator: Bruckner, Brian
Study Coordinator: Bunge, Raquel
Phone: 713-441-6509
Summary:The purposes of this study are to confirm that the Freedom Driver System is a suitable pneumatic driver for clinically stable TAH-t subjects, and that patients and lay caregivers can be trained to man...(read more)

SynCardia TAH-t PM Surveillance Study
Study Status: Active/Enrolling
Investigator: Bruckner, Brian
Study Coordinator: Bunge, Raquel
Phone: 713-441-6509
Summary:The purpose of this study is to demonstrate that the results achieved in the original pivotal clinical investigation of 81 subjects from five clinical sites are generalizable to new clinical sites tha...(read more)
Kidney Transplant

Angion
Study Status: Active/Enrolling
Investigator: Gaber, Ahmed
Study Coordinator: Brann, Sarah
Phone: 713-441-6394
Summary:The objective of the study is to evaluate the safety and activity of a investigational drug in improving renal function in patients who have undergone renal transplantation and have signs and symptoms...(read more)

Eculizumab in the Prevention of A.M.R.
Study Status: Active/Enrolling
Investigator: Gaber, Ahmed
Study Coordinator: Brann, Sarah
Phone: 713-441-6394
Summary:The purpose of this trial is to determine the safety and efficacy of eculizumab in the prevention of antibody mediated rejection (AMR) in living donor kidney recipients requiring desensitization thera...(read more)

LCP-Tacro 3002
Study Status: Active/Enrolling
Investigator: Knight, Richard
Study Coordinator: Brann, Sarah
Phone: 713-441-6394
Summary:This study will evaluate the efficacy and safety of LCP-Tacro (tacrolimus) Tablets administered once-a-day compared to Prograf (tacrolimus) Capsules twice-a-day as immunosuppression for the prevention...(read more)

Single dose vs Traditional Administration Thymoglobulin (S.T.A.T.)
Study Status: Active/Enrolling
Investigator: Gaber, Ahmed
Study Coordinator: Brann, Sarah
Phone: 713-441-6394
Summary:In a non-blinded pilot study conducted at the University of Nebraska Medical Center, evidence was found that a single large dose of Thymoglobulin on the day of kidney transplantation produced better k...(read more)
Liver Transplant

Salix: Rifaximin / Hepatic Encephalopathy study
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.(read more)
Medical Devices

Fistula Plug for Use in Anal Fistula Repair
Study Status: Active/Enrolling
Investigator: Bailey, H. Randolph
Study Coordinator: Cleere, Darrel
Phone: 713-441-6232
Summary:The primary purpose of this prospective, multicenter, observational, single arm study is to substantiate efficacy of the GORE® BIO-A® Fistula Plug when used as a soft tissue reinforcement of anal fist...(read more)
Transplant Related Viral Infections

Cipro for BK Prophylaxis
Study Status: Active/Enrolling
Investigator: Patel, Samir
Study Coordinator: Kueser, Mary
Phone: 7134416311
Summary:BK infection is an important cause of graft dysfunction and graft loss after renal transplantation. It has been widely accepted that emergence of BK virus correlates with the more potent immunosuppres...(read more)

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Active and enrolling clinical trials for Urinary Tract, Sexual Organs, and Pregnancy Conditions are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Kidney Transplant

Angion
Study Status: Active/Enrolling
Investigator: Gaber, Ahmed
Study Coordinator: Brann, Sarah
Phone: 713-441-6394
Summary:The objective of the study is to evaluate the safety and activity of a investigational drug in improving renal function in patients who have undergone renal transplantation and have signs and symptoms...(read more)

Eculizumab in the Prevention of A.M.R.
Study Status: Active/Enrolling
Investigator: Gaber, Ahmed
Study Coordinator: Brann, Sarah
Phone: 713-441-6394
Summary:The purpose of this trial is to determine the safety and efficacy of eculizumab in the prevention of antibody mediated rejection (AMR) in living donor kidney recipients requiring desensitization thera...(read more)

LCP-Tacro 3002
Study Status: Active/Enrolling
Investigator: Knight, Richard
Study Coordinator: Brann, Sarah
Phone: 713-441-6394
Summary:This study will evaluate the efficacy and safety of LCP-Tacro (tacrolimus) Tablets administered once-a-day compared to Prograf (tacrolimus) Capsules twice-a-day as immunosuppression for the prevention...(read more)

Single dose vs Traditional Administration Thymoglobulin (S.T.A.T.)
Study Status: Active/Enrolling
Investigator: Gaber, Ahmed
Study Coordinator: Brann, Sarah
Phone: 713-441-6394
Summary:In a non-blinded pilot study conducted at the University of Nebraska Medical Center, evidence was found that a single large dose of Thymoglobulin on the day of kidney transplantation produced better k...(read more)
Ovarian & Fallopian Tube Cancers

GOG-0225
Study Status: Active/Enrolling
Investigator: Kamat, Aparna
Study Coordinator: Kamath, Jaya
Phone: 713-441-6616
Summary:This randomized phase III trial is studying diet and physical activity changes to see how well they work compared with usual care in improving progression-free survival of patients with previously tre...(read more)
Prostate Cancers

LUTS Pilot - VESI-11E02
Study Status: Active/Enrolling
Investigator: Boone, Timothy
Study Coordinator: Whipple, Melissa
Phone: 713-441-3247
Summary:A single center, pilot trial with combination therapy of tamsulosin and solifenacin in 20 men with symptomatic lower urinary tract symptoms (LUTS). Subjects will be evaluated at baseline, 1, 2, and 3 ...(read more)

Viral Diseases

Active and enrolling clinical trials for Viral Diseases are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Hepatitis Infections

Post-marketing registry of renal safety of HBV+ awaiting liver transplant
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:This registry will remain open for approximately 5 years. Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry. W...(read more)
Transplant Related Viral Infections

Cipro for BK Prophylaxis
Study Status: Active/Enrolling
Investigator: Patel, Samir
Study Coordinator: Kueser, Mary
Phone: 7134416311
Summary:BK infection is an important cause of graft dysfunction and graft loss after renal transplantation. It has been widely accepted that emergence of BK virus correlates with the more potent immunosuppres...(read more)
Viral Infections

Cipro for BK Prophylaxis
Study Status: Active/Enrolling
Investigator: Patel, Samir
Study Coordinator: Kueser, Mary
Phone: 7134416311
Summary:BK infection is an important cause of graft dysfunction and graft loss after renal transplantation. It has been widely accepted that emergence of BK virus correlates with the more potent immunosuppres...(read more)